We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Emily
Peckham
e.peckham@bangor.ac.uk
Ms
Lauren
Walker
Lauren.walker@york.ac.uk
Mood [affective] disordersSchizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
People with severe mental illness (SMI) such as schizophrenia and bipolar disorder have a reduced life expectancy of around 20-25 years compared to those without such disorders (referred to as ‘the mortality gap’).
The causes of the mortality gap are multiple and include chronic, preventable and modifiable physical health problems such as heart disease, chronic respiratory illness, diabetes, smoking and cancers associated with lifestyle, an adverse environment and failures in health services. These diseases can be prevented or moderated via health and lifestyle interventions, and the natural, built and socio-cultural environment in which people with SMI live. Living in deprived circumstances exacerbates the profound inequalities experienced by people with SMI, which have been increasing year on year.
The purpose of this pilot cohort study is to:
i. establish the feasibility of forming a longitudinal cohort of people with SMI
ii. follow up people who took part in the OWLS Study to explore whether and how the COVID-19 pandemic has had any lasting impact on their lives.
Though a series of questionnaires (one questionnaire every six months for five years) will explore the risk factors for smoking, activity levels, diet and alcohol use. In relation to COVID -19 we will continue exploring the effects of the pandemic restrictions, health related behaviours and loneliness. People who took part in the OWLS study and consented to re-contact will be telephoned and invited to take part in the OWLS Cohort. Those who wish to take part will be provided with information about the study and how to take part.
Embedded within this project will be qualitative interviews, the topics explored will be determined by the questionnaire responses and areas identified as needing further exploration. We will seek REC approval for specific interviews via amendment.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients who lack the mental capacity to give consent to participating.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of York and funded by Economic and Social Research Council (ESRC); NIHR Applied Research Collaboration Yorkshire and Humber; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49838
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
